Global Cardiometabolic Drugs 2026-2031 - Rising Cardiometabolic Disease Prevalence Drives Market Growth
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- "Cardiometabolic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Cardiometabolic Drugs Market to Reach USD 621.60 Billion by 2031, Growing at 11.75% CAGR
The global cardiometabolic drugs market is projected to increase from USD 323.41 billion in 2025 to USD 356.75 billion in 2026 before reaching USD 621.60 billion by 2031. The market is expected to register a compound annual growth rate of 11.75% from 2026 to 2031, supported by the rising prevalence of diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, and metabolic liver disease.
Growing Cardiometabolic Disease Burden Drives Treatment Demand
A large diagnosed and undiagnosed patient population continues to create significant demand for cardiometabolic drugs. The International Diabetes Federation reported that 589 million adults were living with diabetes in 2024, including 251.7 million undiagnosed adults. Low- and middle-income countries accounted for 86.9% of undiagnosed cases, highlighting substantial gaps in diagnosis, access, and early intervention.
Delayed treatment can contribute to cardiovascular complications, kidney decline, and metabolic liver disease. As these conditions frequently overlap, healthcare systems are increasingly adopting integrated treatment strategies. This trend is supporting sustained prescription volumes and expanding the use of therapies capable of addressing multiple cardiometabolic risks.
Multi-Indication Therapies Reshape Cardiometabolic Care
GLP-1 and incretin-based therapies are expanding beyond diabetes treatment into obesity management, cardiovascular risk reduction, kidney disease, and metabolic dysfunction-associated steatohepatitis. Wegovy received U.S. Food and Drug Administration approval in August 2025 for adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis, extending its clinical relevance into hepatology.
SGLT2 inhibitors also maintain an important position across type 2 diabetes, heart failure, and chronic kidney disease. Broader indications allow established medicines to reach additional patient groups without requiring entirely new molecular classes. This expansion is encouraging greater collaboration among endocrinologists, cardiologists, nephrologists, hepatologists, and primary care providers.
Affordability and Access Remain Key Market Constraints
High out-of-pocket costs, prior authorization requirements, step therapy, and restrictive reimbursement policies continue to limit access to premium cardiometabolic treatments. Utilization management affected 70% of U.S. exchange-plan drug coverage in 2025. Coverage challenges are particularly significant in obesity care when patients do not have documented diabetes or cardiovascular disease.
Treatment persistence is another important commercial consideration. Manufacturers and healthcare providers must support adherence through appropriate pricing arrangements, patient assistance, clinical monitoring, and convenient dosing formats. Oral and long-acting formulations could reduce administration barriers, while diagnosis and reimbursement expansion may improve access in emerging markets.
Diabetes Leads While Obesity Treatments Record Rapid Growth
Diabetes accounted for 32.4% of the cardiometabolic drugs market in 2025, supported by extensive use of insulin, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. Obesity and weight management is forecast to grow at a 12.5% CAGR through 2031 as new indications and treatment pathways bring obesity care into primary care, endocrinology, and cardiology settings.
Metabolic liver disease remains a smaller segment but is gaining commercial importance. Regulatory authorizations for Rezdiffra in Europe and the United Kingdom, together with the U.S. approval of Wegovy for noncirrhotic MASH, have expanded available treatment options. These developments are reducing traditional boundaries between diabetes, obesity, cardiovascular, renal, and liver disease management.
Lipid-lowering drugs represented 24.3% of the market in 2025. Statins continue to generate substantial prescription volumes, while PCSK9 inhibitors and siRNA-based products support patients with established atherosclerotic cardiovascular disease or statin intolerance. Antihypertensive, anticoagulant, and antiplatelet therapies also remain essential, although mature products face generic competition and price compression.
Semaglutide Maintains a Strong Molecule-Level Position
Semaglutide generated 8.7% of cardiometabolic drug revenue in 2025, reflecting its use across injectable and oral formats and multiple indications. Tirzepatide is projected to grow at a 12.1% CAGR through 2031, supported by its position in diabetes and obesity treatment. Empagliflozin and dapagliflozin remain prominent in heart failure and chronic kidney disease, while atorvastatin, rosuvastatin, apixaban, and rivaroxaban continue to support broad patient access.
Manufacturing capacity and product availability will remain critical to market performance. Injectable peptide therapies require specialized production, fill-finish capabilities, and device assembly. Rapid indication expansion can cause demand to outpace supply, making investment in manufacturing infrastructure and reliable distribution essential.
North America Retains Market Leadership
North America held 41.3% of the global cardiometabolic drugs market in 2025. The region benefits from strong adoption of evidence-based therapies, established specialist networks, and comparatively high branded medicine prices. However, payer controls and evolving U.S. drug-pricing policies are expected to influence reimbursement and revenue growth.
Europe remains the second-largest regional market, supported by a substantial disease burden and structured reimbursement systems. Health technology assessments, pricing controls, and generic competition may restrict revenue, while regulatory progress in metabolic liver disease creates new treatment opportunities.
Asia-Pacific is forecast to record the fastest regional growth, with a 12.2% CAGR through 2031. Large diabetes populations in China and India, expanding healthcare coverage, and improving distribution channels are supporting demand. South America, the Middle East, and Africa also offer long-term growth potential, although affordability, cold-chain infrastructure, and healthcare capacity remain important barriers.
Overall, the cardiometabolic drugs market is moving toward integrated, multi-indication treatment models. Continued innovation in incretin therapies, SGLT2 inhibitors, oral medicines, and long-acting formulations-combined with improved diagnosis and broader reimbursement-will shape global market growth through 2031.
Key Topics Covered:
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cardiometabolic Disease Burden and Treatment Gaps
4.2.2 Multi-Indication Expansion of Incretin and SGLT2 Therapies
4.2.3 Earlier Risk-Reduction Treatment Enabled by Outcome Trials and Guidelines
4.2.4 Emerging-Market Diagnosis and Treatment-Coverage Expansion
4.2.5 Oral and Long-Acting Formats Reducing Administration Friction
4.2.6 Comorbidity-Linked Reimbursement and Real-World Evidence
4.3 Market Restraints
4.3.1 High Out-of-Pocket Costs and Payer Utilization Controls
4.3.2 Generic Erosion and Therapeutic Price Compression
4.3.3 Treatment Discontinuation from Tolerability and Persistence Friction
4.3.4 Counterfeit, Compounded and Gray-Market Product Risk
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porters Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS
5.1 By Therapeutic Area
5.1.1 Diabetes
5.1.2 Obesity & Weight Management
5.1.3 Cardiovascular Diseases (Hypertension, Dyslipidemia, ASCVD, Stroke)
5.1.4 Heart Failure & Cardiorenal Diseases
5.1.5 Metabolic Liver Diseases (MASH/MASLD)
5.2 By Drug Class
5.2.1 GLP-1 & Incretin-Based Therapies
5.2.2 SGLT2 Inhibitors
5.2.3 Insulin & Traditional Antidiabetic Drugs
5.2.4 Antihypertensive Drugs
5.2.5 Lipid-Lowering Drugs
5.2.6 Anticoagulants & Antiplatelet Drugs
5.2.7 Other Cardiometabolic Drugs
5.3 By Molecule / Product
5.3.1 Semaglutide
5.3.2 Tirzepatide
5.3.3 Empagliflozin
5.3.4 Dapagliflozin
5.3.5 Atorvastatin/Rosuvastatin
5.3.6 Apixaban/Rivaroxaban
5.3.7 Other Products
5.4 By Route of Administration
5.4.1 Oral
5.4.2 Injectable
5.4.3 Other Routes
5.5 By Formulation and Dosing Frequency
5.5.1 Tablets & Capsules
5.5.2 Prefilled Pens & Autoinjectors
5.5.3 Vials & Cartridges
5.5.4 Long-Acting Formulations
5.6 By Patient Type
5.6.1 Diabetes Patients
5.6.2 Obesity Patients
5.6.3 Cardiovascular Disease Patients
5.6.4 Cardiorenal Disease Patients
5.6.5 Metabolic Liver Disease Patients
5.6.6 Pediatric & Geriatric Patients
5.7 By Distribution Channel
5.7.1 Hospital Pharmacies
5.7.2 Retail Pharmacies
5.7.3 Online Pharmacies
5.7.4 Institutional & Direct Channels
5.8 By Geography
5.8.1 North America
5.8.1.1 United States
5.8.1.2 Canada
5.8.1.3 Mexico
5.8.2 Europe
5.8.2.1 Germany
5.8.2.2 United Kingdom
5.8.2.3 France
5.8.2.4 Italy
5.8.2.5 Spain
5.8.2.6 Rest of Europe
5.8.3 Asia-Pacific
5.8.3.1 China
5.8.3.2 Japan
5.8.3.3 India
5.8.3.4 South Korea
5.8.3.5 Australia
5.8.3.6 Rest of Asia-Pacific
5.8.4 Middle East and Africa
5.8.4.1 GCC
5.8.4.2 South Africa
5.8.4.3 Rest of Middle East and Africa
5.8.5 South America
5.8.5.1 Brazil
5.8.5.2 Argentina
5.8.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Novo Nordisk A/S
6.3.2 Eli Lilly and Company
6.3.3 Sanofi
6.3.4 AstraZeneca plc
6.3.5 Boehringer Ingelheim International GmbH
6.3.6 Merck & Co., Inc.
6.3.7 Bristol-Myers Squibb Company
6.3.8 Pfizer Inc.
6.3.9 Novartis AG
6.3.10 Bayer AG
6.3.11 Amgen Inc.
6.3.12 AbbVie Inc.
6.3.13 F. Hoffmann-La Roche Ltd
6.3.14 Gilead Sciences, Inc.
6.3.15 Takeda Pharmaceutical Company Limited
6.3.16 Biocon Limited
6.3.17 BioMarin Pharmaceutical Inc.
6.3.18 Cipla Limited
6.3.19 Glenmark Pharmaceuticals Limited
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-Space and Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/u3ep2k
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.